The ₹21.67 crore IPO of Highness Microelectronics launched today, March 24, 2026, with a price band of ₹114–₹120. Operating in the specialized "rugged display" market for medical and defense sectors, the company is looking to fund a new assembly line in Mumbai. With a current GMP of ₹10 (8% gain), we analyze if this SME issue is a "buy" for your portfolio.
One of India’s oldest basmati rice exporters, Amir Chand Jagdish Kumar (Exports) Ltd, is launching its ₹440 crore mainboard IPO on March 24, 2026. With a price band of ₹201–₹212, the company aims to fund its massive working capital needs. We dive into the "Aeroplane" brand’s financials, the ₹6 GMP, and how it stacks up against giants like KRBL and LT Foods.
Hyderabad-based Sai Parenteral's Limited enters the mainboard market on March 24, 2026, with a price band of ₹372–₹392. Specializing in sterile injectables and high-end formulations, the company is using this IPO to fund a major Australian acquisition and a new R&D center. We break down the ₹0 GMP, the 72x valuation, and the risks you should know.
Mumbai-based Speciality Medicines Limited is currently live with its ₹29.14 crore SME IPO. Priced at ₹117–₹124, this 100% fresh issue is a strategic play to pivot from distribution to in-house R&D. With Day 2 bidding underway and a listing scheduled for March 30, we break down the subscription trends, the ₹0 GMP, and the long-term potential.
Electrical switchboard manufacturer Vivid Electromech Ltd is set to launch its IPO on March 25, 2026, with a price band of ₹528–₹555. Boasting a massive revenue jump to ₹155 crore and a 30-year industry legacy, the company is eyeing expansion into new manufacturing units. We break down the financials, the ₹2.66 lakh entry barrier, and what to expect.
The ₹1,842 crore IPO of Coal India’s consultancy arm, CMPDI, is seeing a measured response on its second day of bidding. As of midday March 23, 2026, the issue is subscribed 0.09x, with retail and existing Coal India shareholders showing the most movement. With a Grey Market Premium (GMP) of ₹1.5, the market is pricing this as a long-term "Value PSU" play rather than a quick listing-gain firework.
SME engineering firm Tipco Engineering hits the primary market today, March 23, 2026, with a price band of ₹84–₹89. Despite a flat early Grey Market Premium (GMP), the company’s 4x revenue growth over the last two years and its plans to become debt-free make it a notable entry in the industrial equipment space.
Mumbai-based Highness Microelectronics Limited is set to launch its ₹21.67 crore SME IPO on March 24, 2026. Specializing in high-end, rugged digital imaging and display solutions for the defense, medical, and railway sectors, this "Made in India" tech story is priced at ₹114–₹120. With a shift toward in-house manufacturing and a strong order book, we analyze whether this small-cap contender belongs on your watchlist.
Hyderabad-based Sai Parenteral's Limited is set to launch its ₹409 crore mainboard IPO on March 24, 2026. Specializing in complex sterile injectables and branded generics, the company is pricing its issue at ₹372–₹392. With a 70% profit jump in FY25 and a strategic acquisition in Australia on the horizon, we analyze if this pharma player is a "Long Term" prescription for your portfolio.
Mumbai-based Powerica Limited is set to open its ₹1,100 crore IPO on March 24, 2026. With a strong 40-year legacy in diesel generators and a growing 279 MW wind portfolio, the company is pricing its shares at ₹375–₹395. We dive into the financials, the ₹525 crore debt-repayment plan, and whether this energy hybrid is a "buy" for your portfolio.
The ₹1,842 crore IPO of Central Mine Planning & Design Institute (CMPDI) opens for public subscription on March 20, 2026. As a "Mini Ratna" with a 61% market share in coal consultancy, this debt-free PSU is drawing eyes with its 36.7% ROE. Priced at ₹163–₹172, we break down why the "smart money" just poured in and what the ₹11–₹22 GMP signals for retail investors.
Mumbai-based Speciality Medicines Limited opens its ₹29.14 crore SME IPO on March 20, 2026. With a massive revenue surge to ₹58 crore and a transition from a simple distributor to an R&D-driven pharma player, the company is attracting eyeballs. Priced at ₹117–₹124, we analyze if the strong FY25 financials and low debt make this a "Subscribe" for your long-term portfolio.
GMP IPO Watch
Open IPO
